Loading color scheme

News Releases

15 March 2022

OncoC4 Recognized as a Top 10 Immunotherapy Solutions Providers

ROCKVILLE, Md., Mar. 15, 2022 -OncoC4, Inc. is recognized by Pharma Tech Outlook as one of the "Top 10 Immunotherapy Solutions Providers - 2022".

Read more
18 February 2022

Dr. Pan Zheng of OncoC4 is Inducted into the 2022 College of Fellow of AIMBE

ROCKVILLE, Md., Feb. 18, 2022 -OncoC4, Inc. is elated to announce that its co-founder and Chief Medical Officer, Dr. Pan Zheng, has been selected by the American Institute for Medical and Biological Engineering (AIMBE) to its 2022 College of Fellows.

Read more
09 November 2021

OncoC4, Inc. Reports Phase Ia Data on Safety and Clinical Activities of ONC-392 (Nextgen Anti-CTLA-4) Monotherapy for Stage IV Solid Tumors

ROCKVILLE, Md., Nov. 09, 2021 -- OncoC4, Inc., a clinical stage biopharma company focusing on immuno-oncology of cancer, reports a summary of preliminary clinical data from the ongoing Phase Ia clinical trial (PRESERVE-001NCT04140526) evaluating the safety, tolerability and clinical activity of ONC-392 in cancer patients. ONC-392 is the only clinically tested nextgen anti-CTLA-4 monoclonal antibody that through a unique mechanism recycles, instead of destroys, the CTLA-4 molecules thereby reducing immunotherapy-related toxicity induced by the CTLA-4 depletion while enhancing therapeutic activities.

Read more
27 May 2021

WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership

SHANGHAI and ROCKVILLE, Md.May 26, 2021 -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into an exclusive contract development and manufacturing partnership for OncoC4's full pipeline of biologics including its late-stage project, ONC-392, a next generation CTLA-4 antibody which is under phase I clinical trials in the U.S. and China.

Read more
23 November 2020

Merck to Acquire OncoImmune

KENILWORTH, N.J., & ROCKVILLE, Md.--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and OncoImmune, a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of OncoImmune for an upfront payment of $425 million in cash. In addition, OncoImmune shareholders will be eligible to receive sales-based payments and payments contingent on the successful achievement of certain regulatory milestones. OncoImmune recently announced positive top-line findings from an interim efficacy analysis of a Phase 3 study evaluating its lead therapeutic candidate CD24Fc for the treatment of patients with severe and critical COVID-19.

Read more
23 September 2020

OncoImmune Launches First-in-human Clinical Trial for ONC-392

OncoImmune, Inc. announced today that it has dosed the first patient in the first-in-human clinical trial of ONC-392, its novel, next generation anti-CTLA-4 antibody, at the University of California (UC) Davis Comprehensive Cancer Center on September 16, 2020.

Read more